Ingredient Beauty BenefitsHumectant · Ectoin
Ectoine: there are two randomised trials, and neither measured ectoine on its own
Two randomised trials exist, both in atopic dermatitis. One beat its vehicle but tested a cream that also contained hyaluronic acid; the other tied with a different active cream. Both ran four weeks.
Last checked Sep 20, 2026
At a glance
- In pregnancy
- Not established
- Irritation
- Minimal
- Daytime use
- ✓ Fine
- How well established
- Moderate evidence
- Concentration studied
- 1%
- Length of the studies
- 4 weeks
Not a measurement — reported irritation grouped into five steps. It varies between people.
“Concentration studied” and “Length of the studies” are taken straight from the research on this page. They are not a recommended dose, and the figure for each finding is written out in the text.
This is not how large the effect is but how well confirmed it is. It shows the highest grade among the findings on this page.
Ectoine is an osmolyte made by microbes that live in extreme places — the substance their cells produce to keep from drying out where water is pulled away from them, such as salt lakes.
The hope for skin runs the same way: hold water, slow the barrier drying out. By mechanism it sits where glycerin and hyaluronic acid sit.
This ingredient has two randomised human trials. In this layer that is not a small number.
But neither measured ectoine on its own. One compared a cream containing hyaluronic acid as well against its vehicle; the other compared an ectoine cream against another active cream. Both are set out below.
Contents
What is established
The same ingredient at a different strength, in a different formula, is a different product. These are the conditions the studies used.
It beat its vehicle in children with eczema — but hyaluronic acid was in the cream too
This is a 2023 multicentre trial. 70 children aged 2 to 18 with mild-to-moderate atopic dermatitis (35 per group) were randomised to apply the cream twice daily for four weeks. Observers were blinded; 57 entered the final analysis.
The primary endpoint was change in objective SCORAD, the score a clinician gives for the extent and signs of eczema.
The result: at day 28 the ectoine cream group did significantly better than the control group (P < .001). Secondary endpoints — investigator's global assessment, the patients' own judgement of efficacy, itch — all favoured the ectoine cream too.
Here is the fact that matters most. The product used was a cream containing 1% ectoine and 0.1% hyaluronic acid.
So what the trial showed is not 'ectoine works' but 'this cream, with ectoine and hyaluronic acid in it, did better than the same base alone.' Which of the two contributed how much cannot be read off this design.
The harms, as reported: mild cutaneous adverse events in eight participants (23.5%) on the ectoine cream and two (5.7%) on the vehicle. Mild, but a fourfold difference.
- Randomised controlled trial in people · 70 participants · 4 weeks · Compared with vehicle (same formula minus the active) · Funding not declared · Endpoint clinical events (cancers, lesion counts) PMID 36038984
It tied with another active cream — which is not the same as beating a placebo
This is a 2014 multicentre trial. 65 people aged 18 to 65 with mild-to-moderate atopic dermatitis took part.
The design is unusual: two symmetrical lesions on the same person received the ectoine cream and the control cream respectively — an intra-individual, double-blind comparison. Twice daily for 28 days, assessed at day 7 and day 28 by objective SCORAD and investigator's global assessment.
The result was equivalence. The ectoine cream performed at the level of the reference cream.
Two things to see in that.
First, the comparator was not a placebo. It was a non-steroidal anti-inflammatory cream acting primarily on barrier function — an active product with a comparable mode of action. Two creams tying can mean both worked, or that neither did much. This trial does not separate those.
Second, 'no difference' is not 'the same'. Failing to find a difference between two active creams in 65 people may mean there is none, or that there was no power to find one. Claiming equivalence requires designing and powering for it.
One thing the design does buy: the two sides were on the same person. Differences between individuals cancel out, so a large difference between the creams would likely have shown up here.
- Randomised controlled trial in people · 65 participants · 4 weeks · Compared with another active ingredient · Funding not declared · Endpoint clinical events (cancers, lesion counts) PMID 23949258
How to use it
- Both trials applied it twice a day for four weeks.
- The 2023 trial used 1% ectoine with 0.1% hyaluronic acid. A product with that pairing is closest to what was tested.
- The ectoine content of the 2014 cream is not in the abstract. This site does not estimate concentrations it does not know.
- Moisturising depends more on consistency and how much you apply than on any single ingredient. Read alongside glycerin, ceramides and panthenol.
- An eczema flare is not this ingredient's job. That is a reason to see a doctor.
Cautions
- In the 2023 paediatric trial, mild cutaneous adverse events were 23.5% versus 5.7%, more common on the ectoine cream.
- Both trials ran four weeks. What happens over longer use has not been established.
- We found no randomised trial of ectoine on its own.
- We found no data on use in pregnancy.
With a new ingredient, apply a small amount somewhere inconspicuous, such as the inner arm, for two days first. Stop if it reddens or stings.
Related skin concerns
What this article relies on
- PubMed — 미국 국립의학도서관 문헌 데이터베이스National Library of Medicine · Checked on 2026-09-16